Ensysce Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 6, 2022, reports on a material definitive agreement entered into by Ensysce Biosciences, Inc. on June 30, 2022. The Company, a Delaware corporation, is an emerging growth company focused on biosciences.
Key Financial Metrics and Transaction Details
The Company secured an aggregate financing of $8.0 million through a Securities Purchase Agreement (SPA) with institutional investors. The transaction is structured in two closings:
- First Closing (Completed June 30, 2022): Issued senior secured convertible promissory notes with a principal amount of $4.24 million for a purchase price of $4.0 million. Also issued warrants to purchase 4,667,890 shares of Common Stock.
- Second Closing (Pending): Upon satisfaction of certain conditions, the Company will issue an additional $4.24 million in principal notes for a $4.0 million purchase price and warrants to purchase an additional 4,667,890 shares.
Instrument Terms:
- Notes: 18-month term; 6.0% annual interest; 6% original issue discount (OID); convertible at $0.5450 per share (10% premium to average price prior to closing).
- Warrants: Exercise price of $0.7085 (30% premium to conversion price); 5-year term; exercisable for 60% of shares issuable upon note conversion.
- Redemption: Monthly redemption of 1/15th of principal commencing September 29, 2022. Payments may be made in cash (with 8% premium) or conversion shares subject to specific price and equity conditions.
- Security: Obligations are secured by all Company and subsidiary assets and guaranteed by subsidiaries.
The filing does not provide specific revenue, profit, cash flow, or margin data for the reporting period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Obligations
The primary material change is the creation of a direct financial obligation totaling $8.0 million in aggregate financing. The Company has agreed to register the resale of shares issuable upon conversion of the Notes and exercise of Warrants. The second closing is contingent upon the SEC declaring the registration statement effective, occurring no later than the second trading day thereafter.
Outlook, Risks, and Contingencies
The Company issued a press release on July 1, 2022, regarding this financing. The filing includes standard forward-looking statements cautioning that actual results may differ due to risks and uncertainties. Specific risks include the Company's ability to satisfy conditions for the second closing and the impact of the debt covenants and redemption obligations on future liquidity and capital structure.
Investor Verification Checklist
- Verify the status of the registration statement required for the second closing of the $4.0 million tranche.
- Review the specific "equity conditions" required to pay note redemptions in stock rather than cash.
- Assess the impact of the 6% OID and 6% interest rate on the Company's effective cost of capital.
- Confirm the current cash position to ensure ability to meet the monthly redemption schedule starting September 29, 2022.
- Examine the Security Agreement and Patent Security Agreement to understand the scope of assets pledged as collateral.